Evidence map›Paper›PMID 34725836›Full record

ReviewMedicinal research reviews2022

The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases.

Andrea Magnavacca, Enrico Sangiovanni, Giorgio Racagni, Mario Dell'Agli

Open access · hybridAbstract readReview
In one paragraph

Review in Medicinal research reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Frontiers in pharmacology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrea MagnavaccaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.ORCID 0000-0002-3361-0185
Enrico SangiovanniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.ORCID 0000-0003-2811-8628
Giorgio RacagniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.ORCID 0000-0002-9396-4647
Mario Dell'AgliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.ORCID 0000-0001-5378-402X
University of Milan · IT

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca Progetto di Eccellenza at DiSFeB
6 · The paper itself

Abstract

Propolis is a complex natural product that possesses antioxidant, anti-inflammatory, immunomodulatory, antibacterial, and antiviral properties mainly attributed to the high content in flavonoids, phenolic acids, and their derivatives. The chemical composition of propolis is multifarious, as it depends on the botanical sources from which honeybees collect resins and exudates. Nevertheless, despite this variability propolis may have a general pharmacological value, and this review systematically compiles, for the first time, the existing preclinical and clinical evidence of propolis activities as an antiviral and immunomodulatory agent, focusing on the possible application in respiratory diseases. In vitro and in vivo assays have demonstrated propolis broad-spectrum effects on viral infectivity and replication, as well as the modulatory actions on cytokine production and immune cell activation as part of both innate and adaptive immune responses. Clinical trials confirmed propolis undeniable potential as an effective therapeutic agent; however, the lack of rigorous randomized clinical trials in the context of respiratory diseases is tangible. Since propolis is available as a dietary supplement, possible use for the prevention of respiratory diseases and their deleterious inflammatory drawbacks on the respiratory tract in humans is considered and discussed. This review opens up new perspectives on the clinical investigation of neglected propolis biological properties which, now more than ever, are particularly relevant with respect to the recent outbreaks of pandemic respiratory infections.

Indexed as

PropolisAnimalsAnti-Inflammatory AgentsAntiviral AgentsBeesHumansImmunityImmunomodulationAnti-Inflammatory AgentsAntiviral AgentsPropolisantiviralimmunomodulatorinflammationpropolisrespiratory diseases

Identifiers

PMID34725836
PMCPMC9298305
OpenAlexW3208156870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.